Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients with AIDS or AIDS-Related Complex Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients with AIDS or AIDS-Related Complex conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients with AIDS or AIDS-Related Complex Clinical research trials and A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients with AIDS or AIDS-Related Complex health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients with AIDS or AIDS-Related Complex. A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients with AIDS or AIDS-Related Complex Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients with AIDS or AIDS-Related Complex clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients with AIDS or AIDS-Related Complex condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.

Home > "A" Clinical Trials Conditions > A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients with AIDS or AIDS-Related Complex

A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients with AIDS or AIDS-Related Complex



A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients with AIDS or AIDS-Related Complex

For Condition: HIV Infections,Cytopenias
Status: Completed
Sponsor(s): Amgen ,
Synopsis: To evaluate the safety, tolerance and biological activity of filgrastim (granulocyte colony-stimulating factor; G-CSF) given by daily subcutaneous (SC) injection prior to and concomitantly with erythropoietin (EPO) and zidovudine (AZT) in patients with AIDS or severe AIDS related complex (ARC). To evaluate the safety, tolerance, and biological activity of EPO given 3 times weekly by SC injection concomitantly with G-CSF and prior to and concomitantly with AZT in patients with AIDS or severe ARC. To study the safety and tolerance of 3 dose levels of AZT given to patients with AIDS or severe ARC concomitantly treated with G-CSF and EPO. To study the effect of G-CSF alone and in combination with EPO on HIV replication in vivo as measured by circulating HIV p24 antigen, plasma HIV viremia and semiquantitative HIV cocultures.
Details:
Eligibility:
Study Type:  Interventional, Treatment, Open Label
Minimum Age/Maximum Age: 18 Years/65 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Treatment: Allowed: - Radiation or laser therapy to Kaposi's sarcoma lesions provided the dose does not exceed 3000 rads to any one lesion group and/or greater than 10 cm2 total body surface area. Patients must have: - A diagnosis of AIDS or AIDS related complex (ARC) as defined by current CDC guidelines. - Life expectancy > 6 months. - Defined blood cell counts that may be achieved by transfusion. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - History of malignancy other than Kaposi's sarcoma (KS). - Presence of > 50 cutaneous KS lesions or progression of KS over the previous 30 days. - Presence of opportunistic infection requiring ongoing therapy with known bone marrow suppressive agents. - History of cardiovascular disease. - History of seizures. - HIV related dementia or altered mental status that would prohibit the giving and understanding of informed consent. - Presence of iron deficiency anemia as defined by serum ferritin < 30 ng or iron to TIBC ratio < 15 percent. - A PT > 15 and a PTT > 40 unless due to a documented circulating lupus anticoagulant. Concurrent Medication: Excluded: - Trimethoprim / sulfamethoxazole. - Fansidar. - Non-FDA approved antiretrovirals. - Hyperimmunization with polio virus. - Ribavirin. - Isoprinosine. - Dextran sulfate. - Fu zheng herbs. - AL 721 or its congeners. - Imuthiol. - Interferons. - Chronic use of acyclovir (> 10 days out of 30 days). - = or > 3g/day oral vitamin C. Patients with the following are excluded: - Co-existing conditions and symptoms described in Patient Exclusion Co-existing Conditions. Prior Medication: Excluded within 2 weeks of study entry: - Any non-FDA approved drug. - Excluded within 4 weeks of study entry: - Systemic cytotoxic chemotherapy for Kaposi's sarcoma. - Investigational agents. - Excluded: - Colony stimulating factors. Prior Treatment: Excluded within 4 weeks of study entry: - Radiation therapy for Kaposi's sarcoma exceeding 3000 rads to any one lesion group and/or greater than 10 cm2 total body surface area. Risk Behavior: Excluded within 3 months of study entry: - Regular excessive use of alcohol, hallucinogens or other psychotropic agents which are possibly addicting.
Total Enrollment: 24

Location and Contact Information:

UCLA Med Ctr
Los Angeles,  California,  90095
United States
 


Additional Information:
Study ID Numbers:  061A;  GCSF-8808-109
Study Start Date: 
Record last reviewed: January 1990
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002281

Other Cytopenias Studies:
1. A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV Disease

2. A Comparison of Two Tests for Anti-HIV Drug Resistance

3. Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen

4. A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma

5. A Study on the Safety and Effectiveness of L-756423 Plus Indinavir in HIV-Positive Patients Who Have Previously Taken Indinavir

Related Studies:

Other Cytopenias Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials

A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients with AIDS or AIDS-Related Complex
Modify your Search

  Other Cytopenias Clinical Trials
  Other California Clinical Trials
  Other Los Angeles Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103